 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...4849505152535455565758...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04 (GWCC - B405-B407, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_1777;
P1, P1/2
Notably, minor CAR alterations lead to encouraging in-human activity in early clinical findings. Our experience suggests a shorter linker and hinge as well as incorporation of an CD8 alpha transmembrane region improves the clinical activity of CD22 targeted CAR T cells in subjects with recurrent disease following CD19 CAR T cells.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Observational data, Retrospective data, Journal: Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015-2019: an observational retrospective database analysis. (Pubmed Central) - Nov 5, 2021
This study estimated recent trends of antineoplastic drug use and expenditure for Chinese patients with CRC. These results would inform CRC treatment decisions, including health insurance negotiation, precision therapy access, allocation of research funding and evaluation of the financial burden of CRC drug treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. (Pubmed Central) - Nov 4, 2021
These results would inform CRC treatment decisions, including health insurance negotiation, precision therapy access, allocation of research funding and evaluation of the financial burden of CRC drug treatment. Adverse reaction should be recognized by both dermatologists and oncologists and a multidisciplinary approach is mandatory.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route. (Pubmed Central) - Nov 4, 2021
Mucoadhesive nanoparticles (NPs) based on poly(lactic-co-glycolic acid) (PLGA) and oligomeric chitosan (OCS) were designed as a rational strategy and potential platform to co-deliver alpha-cyano-4-hydroxycinnamic acid (CHC) and the monoclonal antibody cetuximab (CTX) into the brain, by nasal administration...The findings of this work demonstrated the potential of this nanostructured polymeric platform to become a novel therapeutic alternative for GBM treatment. Graphical abstract.
- |||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Monotherapy: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (clinicaltrials.gov) - Nov 4, 2021
P3, N=81, Not yet recruiting, Sponsor: Washington University School of Medicine
Graphical abstract. Initiation date: Sep 2021 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 3, 2021
P1, N=11, Terminated, Sponsor: Northwell Health
Initiation date: Sep 2021 --> Dec 2021 N=21 --> 11 | Trial completion date: Jul 2022 --> Jun 2021 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Jun 2021; Low enrollment
- ||||| pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
New P2 trial, Metastases: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) (clinicaltrials.gov) - Nov 2, 2021
P2, N=280, Not yet recruiting, Sponsor: Sanofi
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery: Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases (clinicaltrials.gov) - Nov 2, 2021
P2, N=100, Recruiting, Sponsor: Yonsei University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
[VIRTUAL] “A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification.” () - Nov 1, 2021 - Abstract #SWOGFall2021SWOG_Fall_419;
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] “Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer” () - Nov 1, 2021 - Abstract #SWOGFall2021SWOG_Fall_394;
- Darzalex IV (daratumumab) / J&J, Erbitux (cetuximab) / Eli Lilly, EMD Serono
NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the Phase 1b dose-escalation study (Poster Hall) - Oct 31, 2021 - Abstract #SITC2021SITC_1300;
P1b/2
NKTR-255, alone and in combination with daratumumab and rituximab, is also being evaluated in liquid tumors. Trial Registration NCT04616196
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Review, Journal, Combination therapy: The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. (Pubmed Central) - Oct 31, 2021
Encorafenib plus cetuximab was evaluated in a randomised phase III trial of encorafenib plus binimetinib plus cetuximab versus encorafenib plus cetuximab versus cetuximab plus irinotecan or FOLFIRI (control arm) to adult patients with BRAFV600E mCRC who had received prior therapy for metastatic disease...The most frequent adverse events in patients receiving encorafenib plus cetuximab were fatigue, nausea, diarrhoea, acneiform dermatitis, abdominal pain, arthralgia, decreased appetite, vomiting and rash. The aim of this manuscript is to summarise the scientific review of the application leading to regulatory approval in the EU.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, P2 data, Journal: nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. (Pubmed Central) - Oct 31, 2021
P2
The cCR rate after nab-paclitaxel and cisplatin was similar to APF; however, the cCR rate after nab-paclitaxel monotherapy was lower. The trial was registered at ClinicalTrials.gov NCT02573493 on October 9, 2015.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal, Circulating Tumor Cells: Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. (Pubmed Central) - Oct 31, 2021
The trial was registered at ClinicalTrials.gov NCT02573493 on October 9, 2015. BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy.
- || Clinical, Review, Journal, Monotherapy, Mismatch repair, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker: The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. (Pubmed Central) - Oct 31, 2021
Pembrolizumab was evaluated in a phase III, open-label, multicentre, randomised trial versus standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab) as first-line treatment of locally confirmed mismatch repair-deficient or microsatellite instability-high stage IV CRC...This is the first time the CHMP has issued an opinion for a target population defined by DNA repair deficiency biomarkers. The aim of this manuscript is to summarise the scientific review of the application leading to regulatory approval in the European Union.
- || CetuGEX (tomuzotuximab) / Glycotope, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study. (Pubmed Central) - Oct 31, 2021
The glyco-engineered antibody tomuzotuximab failed to demonstrate improved efficacy with a chemotherapeutic backbone in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. It remains a so far unanswered question whether such antibody would partner better with different drugs such as checkpoint inhibitors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Stereotactic Body Radiation Therapy (SBRT) With or Without Daily Systemic Therapy for Re-Irradiation of Unresectable, Recurrent, Head and Neck Squamous Cell Carcinoma (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1613;
Systemic therapy with SBRT did not appear to improve LRC or OS over SBRT alone for in the re-irradiation setting of patients with recurrent or second primary squamous cell carcinomas . We found that small tumors (GTV ≤10 cc) may be better suited for SBRT compared to larger ones (GTV >10 cc).
- Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1582;
P1
NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options. NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Stereotactic Body Radiation Therapy (SBRT) in Oropharynx and Oral Cavity Cancer: Toxicity and Local Control (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1580;
SBRT provided comparable control and grade >/=3 toxicity in the oropharynx and oral cavity, with numerically superior control in the oropharynx. No clear relationships were shown between volume of disease, mucosal surface radiation doses, retreatment, control and toxicity, though this analysis is limited by our sample size.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Predictors of Emergency Department Visits and Hospital Admissions During Head and Neck Radiation Therapy (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1559;
Other treatment factors and patient specific factors were not associated with increased EDV/HA. Proactive management of the most common presenting symptoms in this cohort could minimize hospital encounters and improve outcomes.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Head and Neck Stereotactic Body Radiation Therapy Re-Irradiation for Patients With Carotid or Skin Involvement Ineligible for RTOG 3507 (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1546;
There were no CBE related to SBRT in the absence of disease and 31% of patients with pre-SBRT skin involvement exhibited complete healing after SBRT. Consideration of SBRT may still be beneficial for such patients with appropriate counselling.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Radiotherapy vs. Surgery in Early Stage HPV-Positive Oropharyngeal Cancer (Digital XP) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1275;
We found no differences in OS, PFS, and LC between (CC)RT vs. surgery as initial treatment in stage I–II hpv+OPC which warrants comparison via a prospective trial in the treatment de-escalation era. However, most patients undergoing upfront surgery needed adjuvant (CC)RT.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Brachial Plexus Tolerance to High-Dose Radiation in the Re-Irradiation Setting (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_891;
Cumulative incidence of radiation-induced BPP after re-irradiation was 17% at 1 year. Dmax >106 Gy, higher V80/V90, and the use of concurrent cisplatin during re-irradiation, were associated with increased risk of BPP.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lumakras (sotorasib) / Amgen
[VIRTUAL] AMG-510 Plus Cetuximab Enhance Radiosensitivity in KRAS p.G12C Mutant Colorectal Carcinoma Cell Lines via Increasing Apoptosis and Inducing G1/S Arrest (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_887;
The combination of AMG-510 and cetuximab might be a potent treatment as a radiosensitizer. However, more studies in vivo and clinical trials should be performed to further evaluate this regimen in the future.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Risk Factors of Patient-Reported Xerostomia Among Oropharyngeal Cancer Survivors Treated With Definitive Radiotherapy (Digital XP) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_430;
Continued smoking after cancer diagnosis, sex, and education were identified as important risk factors of moderate to severe xerostomia and concurrent cetuximab therapy and more modern RT regimens had a protective association. Sustained smoking post-diagnosis is a modifiable risk factor which can be addressed with continued smoking cessation efforts.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: A p16 Positive M1 Oral Tongue Cancer Completely Responsive to the EXTREME Regimen: A Case Report. (Pubmed Central) - Oct 30, 2021
The treatment regimen unexpectedly proved successful. It may be beneficial to examine p16 expression in oral tongue cancer to identify patients that are more likely to benefit from the EXTREME treatment regimen.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. (Pubmed Central) - Oct 30, 2021
It may be beneficial to examine p16 expression in oral tongue cancer to identify patients that are more likely to benefit from the EXTREME treatment regimen. PD-L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Clinical Trial,Phase II, Journal: Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: A phase II study. (Pubmed Central) - Oct 30, 2021
PD-L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator. LRC compares favorably to historical data examining postoperative radiation alone but requires further investigation.
- BYON4228 is a pan-allelic SIRP_ antibody that potentiates killing of antibody-opsonized tumor cells and lacks binding to T cells. (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_259;
Legal entity responsible for the study The authors. Funding Byondis BV.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Risk Factors of Patient-Reported Xerostomia Among Oropharyngeal Cancer Survivors Treated with Definitive Radiotherapy. (Pubmed Central) - Oct 29, 2021
Sustained smoking post-diagnosis is a modifiable risk factor which can be addressed with continued smoking cessation efforts. Lastly, these results can inform future research and targeted patient-centered interventions to monitor and manage RT-associated xerostomia and preserve QoL among OPC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lumakras (sotorasib) / Amgen
Preclinical, Journal: AMG-510 Plus Cetuximab Enhance Radiosensitivity in KRAS p.G12C Mutant Colorectal Carcinoma Cell Lines via Increasing Apoptosis and Inducing G1/S Arrest. (Pubmed Central) - Oct 29, 2021
The combination of AMG-510 and cetuximab might be a potent treatment as a radiosensitizer. However, more studies in vivo and clinical trials should be performed to further evaluate this regimen in the future.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Brachial Plexus Tolerance to High-Dose Radiation in the Re-Irradiation Setting. (Pubmed Central) - Oct 29, 2021
Cumulative incidence of radiation-induced BPP after re-irradiation was 17% at 1 year. Dmax > 106 Gy, higher V80/V90, and the use of concurrent cisplatin during re-irradiation, were associated with increased risk of BPP.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Head and Neck Stereotactic Body Radiation Therapy Re-Irradiation for Patients With Carotid or Skin Involvement Ineligible for RTOG 3507. (Pubmed Central) - Oct 29, 2021
There were no CBE related to SBRT in the absence of disease and 31% of patients with pre-SBRT skin involvement exhibited complete healing after SBRT. Consideration of SBRT may still be beneficial for such patients with appropriate counselling.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Predictors of Emergency Department Visits and Hospital Admissions During Head and Neck Radiation Therapy. (Pubmed Central) - Oct 29, 2021
Other treatment factors and patient specific factors were not associated with increased EDV/HA. Proactive management of the most common presenting symptoms in this cohort could minimize hospital encounters and improve outcomes.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Stereotactic Body Radiation Therapy (SBRT) in Oropharynx and Oral Cavity Cancer: Toxicity and Local Control. (Pubmed Central) - Oct 29, 2021
SBRT provided comparable control and grade > / = 3 toxicity in the oropharynx and oral cavity, with numerically superior control in the oropharynx. No clear relationships were shown between volume of disease, mucosal surface radiation doses, retreatment, control and toxicity, though this analysis is limited by our sample size.
- || Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P1 data, Journal: Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients. (Pubmed Central) - Oct 29, 2021
P1
NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options. NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Radiotherapy vs. Surgery in Early Stage HPV-Positive Oropharyngeal Cancer. (Pubmed Central) - Oct 29, 2021
However, most patients undergoing upfront surgery needed adjuvant (CC)RT. Pretreatment findings of LN metastases are prognostic as well as predictive for the need of adjuvant treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Stereotactic Body Radiation Therapy (SBRT) With or Without Daily Systemic Therapy for Re-Irradiation of Unresectable, Recurrent, Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Oct 29, 2021
Systemic therapy with SBRT did not appear to improve LRC or OS over SBRT alone for in the re-irradiation setting of patients with recurrent or second primary squamous cell carcinomas. We found that small tumors (GTV ≤10 cc) may be better suited for SBRT compared to larger ones (GTV > 10 cc).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. (Pubmed Central) - Oct 29, 2021
We found that small tumors (GTV ≤10 cc) may be better suited for SBRT compared to larger ones (GTV > 10 cc). Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust anti-tumor response.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II-Mediated Transcription Elongation. (Pubmed Central) - Oct 28, 2021
Our findings indicate that ICP22 interacts with critical elongation regulators to inhibit transcription elongation of cellular genes, which may be vital for HSV-1 pathogenesis. We also show that the HSV viral activator, VP16, has a region of structural similarity to the ICP22 region that interacts with elongation factors, suggesting a model where VP16 competes with ICP22 to deliver elongation factors to viral genes.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 28, 2021
P1/2, N=33, Recruiting, Sponsor: Northwell Health
We also show that the HSV viral activator, VP16, has a region of structural similarity to the ICP22 region that interacts with elongation factors, suggesting a model where VP16 competes with ICP22 to deliver elongation factors to viral genes. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Negative impact of high body mass index on cetuximab-mediated cellular cytotoxicity against human colon carcinoma cells. (Pubmed Central) - Oct 28, 2021
NK cells obtained from subjects who were overweight or with obesity were less efficient in killing cetuximab-treated HT29 cells than those derived from normal weight donors. Our results suggest that the success of cetuximab-containing regimens might be impaired in overweight and obese patients with colorectal cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Precise engineering of cetuximab encapsulated gadollium nanoassemblies: in vitro ultrasound diagnosis and in vivo thyroid cancer therapy. (Pubmed Central) - Oct 28, 2021
Furthermore, we were able to use low-intensity focused ultrasound diagnosis imaging (LIFUS) to examine the efficiency of C-Gd-PFH-NAs in thyroid carcinoma in vivo. These findings clearly show that the use of LIFUS agents with high performance imaging in different therapeutic settings will have extensive potential for future biomedical applications.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, IO biomarker: BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version (Pubmed Central) - Oct 28, 2021
Additional diagnostic tests should also include genome instability (microsatellite instability). Overall, more and more molecular alterations need to be investigated simultaneously, so that the use of focused next-generation sequencing is increasingly recommended.This overview describes the prognostic relevance of BRAF testing in the context of molecular pathologic diagnostics of mCRC, presents new treatment options for BRAF-mutated mCRC patients, and explains which modern DNA analytical and immunohistochemical methods are available to detect BRAF mutations in mCRC patients.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Review: Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review. (Pubmed Central) - Oct 27, 2021
Several EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers have been researched for HNSCC but few of the investigated biomarkers have been adequately confirmed in clinical trials. A more systematic approach is needed to discover proper biomarkers as stratifying patients is essential to prevent unnecessary costs and side effects.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination. (Pubmed Central) - Oct 27, 2021
Our study shows that transcriptome analysis can be used to validate the choice of receptor targets and guide the design of novel multi-specific molecules. The inherent modularity of the AffiMab format renders it readily applicable to other receptor targets.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. (Pubmed Central) - Oct 27, 2021
The inherent modularity of the AffiMab format renders it readily applicable to other receptor targets. Germ line polymorphisms in the PTF genes could be predictive markers for cetuximab in mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. (Pubmed Central) - Oct 27, 2021
Radiotherapy (RT) plus the anti-EGFR monoclonal antibody Cetuximab (CTX) is an effective combination therapy for a subset of head and neck squamous cell carcinoma (HNSCC) patients...Intriguingly, high miR-9 levels have no effect on the sensitivity of HNSCC cells to cisplatin...Overall, we have discovered a new signaling axis linking EGFR activation to Sp1 expression that dictates the response to combination treatments in HNSCC. We propose that miR-9 may represent a valuable biomarker to select which HNSCC patients might benefit from RT+CTX therapy.
- monalizumab (IPH2201) / AstraZeneca, Innate, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Monalizumab, cetuximab and durvalumab in first line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): a phase 2 trial. (Room C [VIRTUAL]) - Oct 27, 2021 - Abstract #ESMOIO2021ESMO_IO_155;
P1b/2
Legal entity responsible for the study Innate Pharma. Funding Innate Pharma and AstraZeneca.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Oct 26, 2021
P=N/A, N=27, Active, not recruiting, Sponsor: Mayo Clinic
Funding Innate Pharma and AstraZeneca. Trial completion date: Dec 2021 --> Dec 2022